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Abstract 
Neuropathic and inflammatory pain results from cellular and molecular changes in dorsal 
root ganglion (DRG) neurons. The type-2 receptor for Angiotensin-II (AT2R) has been 
involved in this type of pain. However, the underlying mechanisms are poorly understood, 
including the role of the type-1 receptor for Angiotensin-II (AT1R). Here, we used a 
combination of immunohistochemistry and immunocytochemistry, RT-PCR and in vitro and 
in vivo pharmacological manipulation to examine how cutaneous inflammation affected the 
expression of AT1R and AT2R in subpopulations of rat DRG neurons and studied their 
impact on inflammation-induced neuritogenesis. We demonstrated that AT2R-neurons 
express C- or A-neuron markers, primarily IB4, trkA and substance-P. AT1R expression was 
highest in small neurons and co-localized significantly with AT2R. In vitro, an inflammatory 
soup caused significant elevation of AT2R mRNA while AT1R mRNA levels remained 
unchanged. In vivo, we found a unique pattern of change in the expression of AT1R and 
AT2R after cutaneous inflammation. AT2R increased in small neurons at 1 day and in 
medium size neurons at 4 days. Interestingly, cutaneous inflammation increased AT1R 
levels only in large neurons at 4 days. We found that in vitro and in vivo AT1R and AT2R 
acted co-operatively to regulate DRG neurite outgrowth. In vivo, AT2R inhibition impacted 
more on non-peptidergic C-neurons neuritogenesis while AT1R blockade affected primarily 
peptidergic nerve terminals. Thus, cutaneous-induced inflammation regulated AT1R and 
AT2R expression and function in different DRG neuronal subpopulations at different times. 
These findings must be considered when targeting AT1R and AT2R to treat chronic 
inflammatory pain.  
 




ABC/DAB: avidin-biotin complex/diaminobenzidine 
ACE: angiotensin converting enzyme 
ARB: angiotensin receptor blocker 
AT1R: Angiotensin II type-1 receptor 
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Azil: azilsartan 
-TubIII: beta tubulin III  
CFA: complete Freund´s adjuvant 
CGRP: calcitonin-gene related peptide 
DAPI: 4’,6´-diamidino-2-phenylindole 
DRG: dorsal root ganglion 
GDNF: glial-derived neurotrophic factor 
HBSS: Hank´s balanced salt solution 
IB4: isolectin B4 
IS: inflammatory soup 
Los: losartan 
LTM: low threshold mechanoreceptor 
MEM: minimum essential medium 
NGF: nerve growth factor 
PD: PD123319 
RRID: research resource identifier (see scicrunch.org) 
SP: substance P 
 
Introduction 
Acute and chronic/pathological pain of peripheral origin results from changes in the activity 
of primary afferent neurons. Different neuronal subpopulations within the dorsal root ganglia 
(DRG) are affected by peripheral inflammation causing lowered nociceptive sensory and 
electrical thresholds in undamaged fibers (Djouhri et al. 2012; Shim et al. 2005) as well as 
spontaneous pain, mechanical allodynia and hyperalgesia (Cook et al. 2018; Djouhri et al. 
2006; Pinho-Ribeiro et al. 2017). Recently, the renin-angiotensin system (RAS) has been 
shown to be involved in normal and pathological sensory function, including inflammation 
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II), which is released during inflammation (Suzuki et al. 2003), interacts with both angiotensin 
type-1 receptor (AT1R) and angiotensin type-2receptor (AT2R) present in the DRG and 
other peripheral nervous system structures although their role in sensory pathways has yet 
to be fully understood (Patil et al. 2010; Pavel et al. 2008; Smith & Muralidharan 2015). 
The most widely used antihypertensive drug classes, angiotensin converting enzyme (ACE) 
inhibitors and Ang-II receptor blockers (ARBs), are used to treat inflammatory diseases 
through actions independent of their effects on blood pressure (Ranjbar et al. 2019). Of 
notice, AT1R are up-regulated in inflamed tissues. On the other hand, the trend in emerging 
data supports anti-inflammatory, anti-proliferative and anti-fibrotic roles for AT2Rs, and they 
also may protect against oxidative stress (Matavelli & Siragy 2015). In fact, it is thought that 
AT1R and AT2R in general have opposite effects on several cell functions (Chabrashvili et 
al. 2003; Jones et al. 2008). However, Ang-II activation of AT2R acting through the NF-κB 
pathway led to pro-inflammatory responses (Esteban et al. 2004; Wolf et al. 2002). These 
data indicates that the correct functioning of the RAS system demands a complex and finely 
tuned balance between activation of the two receptors. 
The inherent pharmacological consequences of such an integrated mechanism of action are 
perhaps most clearly seen with Ang-II associated analgesia. Chronic administration of AT1R 
antagonists has been shown to ameliorate migraine and neuropathic and nociceptive pain 
(Bali et al. 2014; Marques-Lopes et al. 2009) whilst selective AT2R antagonists have been 
proposed as a treatment for chronic inflammatory pain and peripheral neuropathy (Smith & 
Muralidharan 2015; Smith et al. 2013; Shepherd & Mohapatra 2018). It is unclear whether 
the beneficial effects of RAS blockers in models of neuropathic pain are mediated directly 
through action on sensory pathways, or indirectly through their attenuating effects on pro-
inflammatory mediators. 
There is contradictory evidence regarding the nociceptive effect of activating or blocking the 
AT2R. For instance, a newly identified natural agonist of AT2R, mycolactone, induces 
analgesia in patients with Buruli ulcers (Marion et al. 2014). Both AT2R agonists and 
antagonists can have an anti-nociceptive effect under different circumstances. Evidently, a 
deeper knowledge of the mechanisms of action of Ang-II on the inflammatory responses, 
and on the ability of ARBs to decrease pain perception, would clarify these apparently 
contradictory results. One such mechanism involves the Ang-II release in response to 
inflammation (Benigni et al. 2010) acting on AT2R to promote neurite outgrowth in cultured 
cells of neuronal origin (Guimond & Gallo-Payet 2012; Li et al. 2005; Namsolleck et al. 2013) 
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Chakrabarty et al. 2008). In this respect, evidence suggests that structural plasticity of 
peripheral sensory innervation may play a main role in pain sensation (Cain et al. 2001). 
Prior observations provided indirect pharmacological evidence for the involvement of AT2R 
in relieving mechanical allodynia after CFA injection (Chakrabarty et al. 2013). However, it is 
unclear what role AT1R and the interaction between AT1R and AT2R play in inflammatory 
processes, particularly in identified neuronal subpopulations of DRG neurons as they 
mediate different sensory modalities. To address this, we carried out a phenotypic 
characterization of the AT1R and AT2R expressing DRG neurons, and examined how their 
expression changed in these neuronal subpopulations after induction of cutaneous 
inflammation. We also looked at Ang-II-induced neuritogenesis in DRG neurons in vitro and 
in vivo, and the relative contributions of AT1R and AT2R activation to this process. 
 
Materials and Methods 
Animals 
We used 3 month old female Wistar rats (RRID:RGD_737929; weight range 175-200g 
obtained from Servicio de Animales de Laboratorio, Facultad de Ciencias Veterinarias, 
Universidad Nacional de La Plata, Argentina) for in vivo experiments (initial n=33) and 
postnatal day 15 (P15, n=15) for primary DRG cell cultures. Animals (3 per cage) were 
housed in large metallic boxes with wire mesh lids under controlled temperature and 
humidity with 12h light/darkness cycles and access to food and water ad libitum. All 
experimental procedures were carried out between 9-11 AM. Animals were cared for in 
accordance with the Guiding Principles in the Care and Use of Animals of the US National 
Institute of Health. All procedures were approved by the Institutional Animal Care and Use 
Committee (CICUAL 31/2014 and 102/2017) of the Universidad Nacional de Cuyo, 
Mendoza, Argentina. 
 
Induction of cutaneous inflammation 
Cutaneous inflammation was induced under sevofluorane anesthesia by intradermal 
injection of 100 μl Complete Freund's Adjuvant (CFA, Sigma, Cat# F5881) as previously 
described (Haskins et al. 2017). To examine the expression of AT1R and AT2R, DRG were 
removed after 1 day (CFA1, n=5 rats) and 4 days after CFA (CFA4, n=5 rats). Control rats 
(n=5) received a single injection of 100 µl sterile saline solution. Animals were allocated to 
each experimental group using a random sequence generator 
(https://www.random.org/sequences/). Rats were numbered from 1 to 15, and then assigned 
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identifier number) to each group until all had 5 rats each. Notice that a randomized sequence 
does not contain duplicates (Kim & Shin 2014) . No exclusion criteria were pre-determined 
and no animals died during the experiments. Because the CFA treatment can cause mild to 
moderate pain, we observed the behavior of the rats twice a day looking for signs of 
significant discomfort (like failure to groom etc.). We also weighed them daily and measured 
their consumption of water and food. Any rats exhibiting a 10% weight loss or a 20% drop in 
water/food intake would be terminated by humane culling. This, however, was not needed. 
Analgesia was not provided as most analgesics have anti-inflammatory activity or are 
opioids, and both will interfere with the aims of the study.  
 
Tissue preparation 
After treatment, rats were anesthetized with ketamine (Cat# 01750020010)  plus xylazine 
(Cat# 01750020170, both from Richmond VetPharma) (50 mg/kg & 10 mg/kg) i.p. and 
transcardially perfused with saline supplemented with heparin (10 UI/ml, Sigma, Cat# 
H3393) followed by Zamboni's fixative (Stefanini et al. 1967). Next skin, L5 DRGs, spinal 
cord, dorsal root, spinal and sciatic nerve were dissected and post-fixed for 20 min in 
Zamboni's at RT and dipped in sequentially through graded sucrose solutions (from 10 to 
30%) at 4°C. Tissue was frozen and kept at -80ºC until used. Serial 7 μm cryostat sections 
were cut for all tissues except skin (10 μm) and spinal cord (12 µm). Sections were placed 
on gelatin-coated slides and stored at -20°C for subsequent immunoassays. 
 
Primary antibodies against AT1R and AT2R 
We used a goat anti-AT2R from Santa Cruz Biotechnology (Cat# sc-48452, K15, RRID: AB 
2225720, 1:200) also used in the DRG by (Anand et al. 2013) and other cell types (Dolley-
Hitze et al. 2010). We chose this antibody because of concerns about the selectivity of other 
commercially available antibodies against AT2R (Hafko et al. 2013). A polyclonal rabbit anti-
AT1R (Santa Cruz Biotechnology Cat# sc-579, RRID: AB_2225713, 1:200) was used 
(Buttler et al. 2017). We performed a further characterization of these antibodies comparing 
them against 2 other commercially available anti-AT2R antibodies (Suppl. Fig. 1). To do this, 
we ran Western blot analysis and found that AT1R (306) and AT2R (K-15) both detect a 
single band of the predicted molecular weight in DRGs of 3 different ages and also in the 
spinal cord (A-B). However, anti-AT2R (H-143) marked a large number of additional bands 
(C). Next, we examined how the antibodies performed at staining adrenal gland, a known 
physiological target for Ang-II where the distribution of AT1R and AT2R expression has been 
reported using non-immune methods. We found that AT1R (306) and AT2R (K-15) but not 
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medulla as expected (Johren et al. 1995; Macova et al. 2008; Pavel et al. 2008). We found 
that AT1R (306) selectively stained motoneurons in the ventral horn of the spinal cord (Pavel 
et al. 2008) while AT2R (K-15) was remarkably more selective than Alomone´s AAR-012 
staining DRG neurons. K-15 also stained cortical neurons, in agreement with reports using in 
situ hybridization (Lenkei et al. 1997). 
 
Other primary antibodies and IB4-binding 
We used phenotypic markers of neuronal subpopulations: 1) Staining with isolectin B4 (IB4, 
Cat# B-1205, RRID:AB_2314661,1:400), which labels small, C- neurons (Fang et al. 2006). 
2) Mouse anti-NF200 (clone RT97, RRID:AB_528399, DSHB, Iowa University, 1:4000). 3) 
Rabbit anti-TrkA (Millipore Cat# 06-574, RRID:AB_310180, developed by L. Reichardt; 
1:1000). 4) Guinea pig affinity purified anti-Substance P from Neuromics (Cat# GP14110, 
RRID:AB_2315368, 1:500). 5) Rabbit anti-CGRP (1:2000) characterized by (Gibson et al. 
1984) and validated by (Lawson et al. 1996). A mouse anti-β-tubulin III (-TubIII) antibody 
was also used (clone SDL.3D10, Cat# ab11314, RRID:AB_297918, 1:1000). A rabbit anti-
PGP9.5 was also used to estimate total neurite length in vitro (Cat# RA12103, Neuromics, 
RRID: AB_2315126, 1:400). 
 
Western blotting 
Western Blots were performed as previously described (Acosta et al. 2014; Benitez et al. 
2017) (Suppl. Fig. 1). Total protein was extracted from whole L4/L5 DRGs and spinal cord 
using Laemmli buffer supplemented with a protease/phosphatase inhibitor cocktail (HALT, 
Cat# 87786, Thermofisher). Samples of ∼10 μg of total protein were run on 8% 
polyacrylamide gels and transferred to PVDF membranes (Cat# GE10600023, Amersham) 
before blotting. Membranes were blocked with 5% semi-skimmed milk dissolved in tris-buffer 
saline (TBS) during 1h at RT and then probed overnight with 1:500 polyclonal rabbit anti-
AT1R (306) or 1:1000 goat anti-AT2R (K-15) or 1:1000 rabbit anti-AT2R (H-143). We used 
1:4000 mouse anti-α-tubulin (eBioscience, Cat# 14–4502-80, RRID:AB 1210457) as loading 
control. The membranes were washed three times for 5 mins with 0.1% Tween 20 in TBS 
(TBST) and then blocked again with 5% semi-skimmed milk for 30 min before incubation for 
2h at RT with either 1:2000 peroxidase-labeled anti-rabbit (Cat# PI-1000, 
RRID:AB_2336198) or anti-goat (Cat# PI-9500, RRID:AB_2336124) both from Vector 
Laboratories. The membranes were washed 3 times for 5 min with TBST and twice for 5 min 
with TBS. Protein bands were developed using ECLPlus (Amersham) and visualized with the 
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Immunohistochemistry 
Avidin-biotin complex (ABC/DAB) immunohistochemistry was carried out following previously 
published protocols (Acosta et al. 2014).  
Sections were incubated in primary antibody (anti-AT2R 1:200 or anti-AT1R 1:200) diluted in 
0.05% Triton X-100 in PBS buffer (PBST) overnight at 4°C. On the following day, sections 
were incubated with biotinylated horse anti-goat (Cat# BA-9500, RRID:AB_2336123) or anti-
mouse (Cat# BA-2001, RRID:AB_2336180) antibodies (1:400) (Vector Laboratories) for 30 
min at room temperature. After washings with PBST, sections were incubated 30 min with 
Streptavidin-HRP (1:200, Cat# S5512, Sigma). To develop the reaction, an ABC standard kit 
from Vector Laboratories was used (Cat# PK-4000, RRID:AB_2336818). For comparisons 
between different treatments, all sections were incubated simultaneously for the same length 
of time. 
Double/triple immunofluorescence was conducted as previously described (Benitez et al. 
2017). Tissues were incubated sequentially in the first primary antibody overnight at 4°C and 
in secondary antibody appropriate for that primary antibody or IB4 for 2hr at room 
temperature. Anti- AT2R was used at 1:200, anti-AT1R at 1:200, anti-TrkA at 1:1000, anti-
NF200 at 1:4000, anti-Substance P at 1:500, anti--TubIII at 1:1000 and anti-CGRP at 
1:2000. Secondary antibodies were 1:400 donkey anti-rabbit Alexa-488 (Cat# A32790, 
RRID:AB_2762833) or Alexa-594 (Cat# A32754, RRID:AB_2762827), goat anti-rabbit 
Pacific blue (1:100, Cat# P_10994, RRID:AB_2539814), 1:400 goat anti-mouse Alexa-488 
(Cat# A_21141, RRID:AB_2535778) or Alexa-594 (Cat# A_21145, RRID:AB_2535781), 
1:400 goat anti-guinea pig Alexa-594 (Cat# A_11076, RRID:AB_2534120) and donkey anti-
goat Alexa-488 (Cat# A32814, RRID:AB_2762838) or Alexa-594 (Cat# A32758, 
RRID:AB_2762828), all from Invitrogen. IB4 was conjugated with either FiTC or DyLight 594 
(1:500, Vector Laboratories, Cat# DL_1207). 
 
Cell cultures 
DRGs from all rostrocaudal levels from P15 rats, one per culture, were dissected out 
following previously detailed protocols (Acosta et al. 2014; Acosta et al. 2012). We choose 
this age because a) the neurons have a better survival profile than adult neurons; b) they 
attached well to a collagen substratum unlike older, adult DRG neurons and c) we have 
already demonstrated that they express levels of AT2R similar to that of adult DRG (Benitez 
et al. 2017). Briefly, the ganglia were enzymatically digested at 37°C in 0.625% trypsin (Cat# 
27250018) for 25 min and then with 0.5% collagenase (Cat# 17100017) for 20 min in HBSS 
(Hank’s Balanced Salt Solution) subsequently quenched with DMEM/F12 (Cat# 11320033) 
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were plated onto round coverslips (Bellco Glass, Germany) previously coated with rat tail 
collagen (300 ng/mm2). Neurons were allowed to attach to the substratum for 3-4 h before 
addition of DMEM/F12 supplemented with N2 medium (Cat# 17502001) and 
penicillin/streptomycin (Cat# 15140122). Enzymes, N2 and antibiotic were obtained from 
GIBCO Thermo Fisher. Non-neuronal cell proliferation was controlled from the start with 10 
µM Cytosine β-D-arabinofuranoside (Sigma, Cat# C6645). Cells were kept at 37°C in a 5% 
CO2 incubator. 
In vitro treatment with inflammatory soup 
Three cultures (from 3 rats) were divided in two groups: one group with no trophic factors 
(NTF) or for 1 day in vitro (1DIV) with mouse NGF 7S (10 ng/ml, Cat# 450-01) or rat 
recombinant GDNF (20 ng/ml, Cat# 450-10) (Peprotech). We chose NGF as AT2R+ and 
AT1R+ neurons co-localized with trkA (the high affinity receptor for NGF). As most AT2R+ 
neurons also bound IB4, we tested GDNF, the trophic factor on which IB4+ neurons depend 
(Dubin & Patapoutian 2010). The other group received in addition an inflammatory soup (IS) 
containing: 10 μM histamine (Cat# H7125), 10 μM -methylene ATP (Cat# M6517), 1 μM 
prostaglandin-E2 (Cat# P0409), 1 μM bradykinin (Cat# B3259), 10 μM serotonin (Cat# 
H9523), 100 nM IL-6 (Cat# I0406), 1 μM TNF-α (Cat# T5944) and 1 µM substance P (Cat# 
S6883). All drugs obtained from Sigma. These are referred to as NTF+IS, NGF+IS and 
GDNF+IS.  
 
In vitro treatment with Ang-II 
Another 3 cultures (from 3 rats) received daily doses of NGF 7S (10 ng/ml), Ang-II (20 nM, 
Cat# GPA-100) alone or in combination with AT1R/AT2R selective blockers: 10 nM 
azilsartan (Cat# A-245) and/or 50 nM PD123319 ditrifluoroacetate (Cat# P-245, all from 
Alomone Labs, Israel). The cultures were pre-incubated for 15 min at 37°C with the 
antagonists before addition of Ang-II. Control cultures received neither trophic factors nor 
Ang-II. Neurons were treated for 2 days (2DIV) to allow measurement of neurite outgrowth. 
 
Semi-quantitative RT-PCR 
Specific mRNA levels from 3 cultures with or without IS were determined by RT-PCR as 
previously described (Kunda et al. 2014; Marsh et al. 2012; Benitez et al. 2017). mRNA was 
extracted using RNeasy (Cat# 74104, Qiagen). Total mRNA was quantified using a 
Nanodrop and only samples with an A260:A280 ratio above 1.8 were used. cDNA was 
synthesized from 200 ng total RNA using the M-MLV kit (Cat# 9PIM170, Promega) 
supplemented with RNAseOut (Cat# 1077719, Thermo Fisher). AT2R and AT1R mRNA 
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consisted of 2 min at 94ºC, 34 cycles of 20 sec at 94ºC, 20 sec at 60ºC and 45 sec at 72ºC, 
followed by 5 min at 72ºC as final extension. For AT1R the program was 3 min at 94ºC, 34 
cycles of 1 min at 94ºC, 1 min at 58ºC and 45 sec at 72ºC, followed by 15 min at 72ºC. -
actin mRNA was used as loading control (32 cycles). We performed a negative control 
containing RNA instead of cDNA to rule out genomic DNA contamination.  
Primers sequences were: AT2R forward: 5’-CAACTTCAGTTTTGCTGCCAC-3’; reverse 5’-
CAGGTCCAAAGAGCCAGTCAT-3’, predicted product size 335 bp. AT1R forward: 5’-
ATCCAAGATGACTGCCCCAA-3’; reverse 5’-GCCAAGGCGAGATTGAGAAG-3’, predicted 
product size 179 bp. -actin forward: 5’-CGGAACCGCTCATTGCC; reverse 5’-
ACCCACACTGTGCCCATCTA -3’, predicted product size 290 bp. All primers were 
synthesized by Ruralex (Argentina), custom-designed and checked for specificity using 
Primer-BLAST. Images of the RT-PCR SYBR Safe (Cat# S33102, Thermo Fisher) stained 
agarose (Cat# A9539, Sigma) gels were acquired with the LAS-4000 system (Fujifilm) and 
quantified with ImageJ software (Benitez et al. 2017). 
 
Immunocytochemistry 
Cultures were removed from the incubator, washed 2 times with PBS and then fixed in 4% 
PFA (Cat# P6148, Sigma) with 4.2% sucrose (Biopack, Argentina) for 20 min at 4ºC, 
washed again with PBS and permeabilized with 0.2% v/v Triton X-100 (Biopack, Argentina). 
Non-specific binding sites were blocked by 1 h incubation at room temperature with 5% BSA. 
Triple immunofluorescence was performed as previously reported (Acosta et al. 2014; 
Acosta et al. 2012). Coverslips were incubated sequentially in the first primary antibody 
overnight at 4°C and then in fluorescent secondary antibody appropriate for that primary 
antibody for 1 h at room temperature. This cycle was repeated for each primary antibody. 
Coverslips were mounted with Mowiol 4-88 (Cat# 475904, Merck). Primary antibodies were 
applied following the sequence: mouse anti-β-TubIII (1:500), goat anti-AT2R (1:200) and 
rabbit anti-AT1R (1:200). Secondary antibodies were donkey anti-mouse DyLight 549 
(1:400, Vector Labs, Cat# A17828), donkey anti-goat DyLight 488 (1:200, Vector Labs, Cat# 
SA5-10086, RRID:AB_2556666) and goat anti-rabbit Pacific Blue (1:200). 
 
In vivo inhibition of Ang-II receptors  
In order to examine the role of AT1R and AT2R on in vivo neuritogenesis we divided 18 rats 
in 3 experimental groups (see Fig. 1). Rats were allocated to each experimental group using 
the same procedure described above (see Induction of cutaneous inflammation)  but starting 
up with 18 numbered rats. One group (n=6) was given oral Losartan (potassium salt, 
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The amount of daily drug ingested by each rat was calculated based on the total volume of 
water drank divided by the number of rats in each cage. This rendered an effective average 
dose of losartan of 20 mg/Kg/day. This dosage and length of treatment was used elsewhere 
to examine numerous physiologically relevant processes (Akershoek et al. 2017; Bayar et al. 
2015; Kamber et al. 2015). The second group (n=6) received oral losartan as the first group, 
but from day 25 to 28 also received a daily i.p. injection of PD 123319 (1mg/Kg/day 
(Sanchez et al. 2008)). Our aim was to assess the effect on neuritogenesis of acutely 
antagonizing AT2R in rats where AT1R was already suppressed. Control group (n=6) 
received normal drinking water (NDW). On day 28, cutaneous inflammation was induced in 
all rats as described above.  
 
Image acquisition and analysis 
All analyses were performed as previously detailed in (Acosta et al. 2014; Benitez et al. 
2017) on images captured on a Nikon 80i microscope and the quantification was performed 
using HCImage (Hamamatsu, RRID:SCR_015041). For each experimental comparison, 4-6 
fields were captured at 40X with identical settings during the same session. All intensity 
measurements were carrried out at the soma as it is assumed that soma levels are similar to 
those present at the nerve terminals. This quantitative analysis was the only one performed 
blindly. 
AT2R-AT1R intensities measurement: Only neurons with visible nuclei from mid-sections of 
L5 DRGs were measured. The cross sectional area and mean whole cytoplasmic, edge and 
inner pixel density were determined for each neuron. We used cytoplasmic levels as 
indicative of the total available protein including newly synthesized receptors. In the case of 
the whole cytoplasm, nuclei were excluded. For edge we drew a line (thickness 3 pixels) 
over the cell perimeter, that likely reflects the amount of the receptor close to or in the 
plasma membrane). For the perinuclear intensity we also drew a line over the region 
surrounding the nucleus (from here on inner) (Suppl. Fig. 2). In both cases, the software 
averages the pixel density (as mean grey) for the entire region under the line. We have used 
a similar approach to measure membrane-associated (edge) and inner staining for TREK2 
(Acosta et al. 2014), 3-Na+/K+-ATPase (Parekh et al. 2010) and HCN1/HCN2 (Acosta et 
al. 2012) in the DRG. The mean pixel densities for each region of the 5 most intensely 
stained and the 5 least intensely stained neurons in the analyzed section provided 100% and 
0% values respectively. All pixel densities were converted to % intensities as described in 
(Acosta et al. 2014; Benitez et al. 2017; Haskins et al. 2017). Neurons were classed by size: 
small (those with areas <400 μm2), medium (400 to 800 μm2) and large (>800 μm2) (Lawson 
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percentage values of neurons that were blindly classed subjectively as clearly stained above 
background. A subjective score of 1 (visible staining) corresponded to objective AT1R/AT2R 
values of ≥20% above background which were therefore classed as positive. 
Neurite length measurement in DRG cell culture: 40X images were captured blindly to avoid 
biased data acquisition. For image analysis, we drew lines over all visible neurites labeled 
with -TubIII and measured their length. Then, for each image, we calculated the neurite 
length per neuron.  
Quantification of nerve terminals in hindpaw skin sections: 10-12 20X randomized images 
covering most of the section in the epidermal region were captured blindly. Nerve fibers were 
identified by staining for -TubIII. CGRP labels peptidergic  (likely trkA+) C- and A-fiber 
neurons while IB4 binds primarily to small unmyelinated C-nociceptor fibers. Due to the fact 
that IB4 also stains endothelial cells and other non-neuronal cell types (Laitinen 1987), we 
only quantified as IB4+ nerve terminals those that were also strongly stained for -TubIII. All 
visible nerve terminals labeled with -TubIII/IB4 or -TubIII/CGRP were sketched and their 
lengths measured with HCImage. We also measured the whole area encompassing the 
epidermis and the dermis, and this value was used to calculate neurite length per area. 
Thickness of the epidermis: we measured the thickness of the epidermis (without stratum 
corneum) in the contralateral and ipsilateral hindpaw of CFA1 rats with or without AT1R and 
AT2R antagonists (see above). This was done in images taken from 3 serial sections (10 
sections in between) of the hindpaw skin per rat, at 20X magnification. The thickness of the 
dermis was measured using a straight line extending from the basal epithelium of the 
epidermis to the beginning of the stratum corneum in 10 locations per section (Leiguarda et 
al. 2018). 
Hindpaw dorsoventral thickness measurement 
Hindpaw dorsoventral thickness was measured by positioning a caliper touching both the 
ventral and dorsal surfaces of the hindpaw. Care was taken not to compress the hindpaw 
during measurement. 
Statistics 
Results are shown as means±SEM. The n values are provided in the figure legends.  The 
normality of data was assessed with the D’Agostino-Pearson test. For data sets that failed 
the normality test, correlations were evaluated using the non-parametric Spearman´s test 
(Spearman’s correlation coefficient, rs, given when significant). Comparisons between 
multiple treatment groups were performed with Kruskal-Wallis test plus Dunn’s multiple 
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Tukey’s multiple comparisons test (Fig. 7G and Suppl. Fig. 4). Comparisons between two 
treatments groups were evaluated using Mann-Whitney U test (Figs. 4A-B, 8A-C and Suppl. 
Fig. 5). All tests were performed with Prism 7 (GraphPad software, RRID:SCR_000306). No 
sample calculation was performed. We did not conduct any data test for outliers and thus no 
single data points were excluded. Tests were two-tailed and a level of p<0.05 was 
considered statistically significant. Significance is indicated on all graphs by *p<0.05, 
**p<0.01 and ***p<0.001. 
 
Results 
Phenotype of DRG neurons expressing AT2R and AT1R 
Small and medium size neurons are strongly stained for AT2R (black arrows, Fig. 2A). Large 
neurons (asterisks) show little or no staining. Satellite cells show some weak staining. 
Quantitative image analysis of 251 neurons from L5 mid-sections (n=5 rats) showed that 
AT2R cytoplasmic intensity was significantly and negatively correlated with cell area 
(Spearman´s correlation rs=-0.61, P<0.0001, Fig. 2A). AT2R mean±SEM percentages of 
cytoplasmic staining were similar for small and medium DRG 61.0±2.2%  vs. 54.1±3.1% 
respectively with significantly lower levels in large neurons (6.9±1.0%, p<0.001).  
A similar analysis was conducted for AT1R expression in normal L5 DRG. Although sensory 
neurons of all sizes expressed AT1R, we observed a negative and statistically significant 
correlation between AT1R cytoplasmic intensities and cell area (rs=-0.49, p<0.0001, Fig. 2B). 
The mean (±SEM) percentage levels of cytoplasmic AT1R differed significantly for small 
(61.2±3.1%), medium (46.5±2.6%) and large (29.2±3.0%, p<0.001) neurons. 
We next examined the co-expression of AT2R and AT1R, as this is of fundamental 
importance to assess the role of Ang-II on these neurons. White arrows in Fig. 2C indicate 
AT2R+ neurons that are also AT1R+. Most AT2R+ neurons were also AT1R+ (188 out of 
194, 97%) whereas about 80% (188 out of 234) of the AT1R+ neurons were also AT2R+. 
Thus, the majority of angiotensin-sensitive neurons in the DRG express both receptors. 
We next characterized the sensory neuron subpopulation that expressed AT2R. Fig. 2D 
shows the typical pattern of expression for AT2R, binding of IB4 and trkA. As we reported 
previously (Benitez et al., 2017) most AT2R+ neurons bind IB4, albeit there are some small 
and medium sized DRG neurons who exhibit co-localization of AT2R and trkA. Analysis 
reveals a positive and significant correlation between AT2R and IB4 (rs=+0.49, p<0.0001) 
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We occasionally observed punctate, Golgi-like, low intensity AT2R staining in a few large 
neurons. To determine which type of myelinated A-neurons they were, we examined the co-
localization of AT2R with a marker for myelinated DRG neurons (RT-97) and trkA (as a label 
for A-nociceptors (Fang et al. 2005a)). We found few neurons that evinced at once tenuous 
AT2R labeling, were trkA+ and had visible RT97 (white arrow in Fig. 2F).  
Projections of AT2R+ sensory neurons 
We found AT2R staining mostly in laminae I and II of the dorsal horn of the spinal cord, 
where it co-localizes partially with IB4 (Fig. 3A), and remarkably well with substance P (Fig. 
3F). We also observed substantial axonal co-localization of AT2R with IB4 and SP in the L5 
dorsal root as well as in the L5 spinal nerve (indicated by white arrows in Figs. 3B-C and G-
H). In both cases, some fibers (indicated by arrowheads) were AT2R+ but negative for either 
IB4 (Fig. 3B-C) or SP (Fig. 3G-H). As expected, AT2R staining co-localized well within a 
subset of IB4+ fibers in the sciatic and especially in the sural division of the sciatic nerve 
(indicated with an arrow, Fig. 3D). Finally, free terminals of C-fiber IB4+ neurons in the skin 
(white arrows) and nerve bundles (asterisk) were AT2R+ (Fig. 3E).  
Inflammatory soup up-regulates AT2R but not AT1R in vitro 
Selective blockade of AT2R with EMA401 reverted mechanical allodynia associated with 
cutaneous inflammation (Anand et al. 2015; Chakrabarty et al. 2013). However, the 
mechanism underlying this effect is poorly understood and so is the possible involvement of 
AT1R. 
Real-time semi-quantitative PCR analysis of 3 separate DRG cultures showed that addition 
of an IS for 24h caused a significant elevation of AT2R mRNA for all three conditions (NTF 
vs. NTF+IS p=0.0014; NGF vs. NGF+IS p=0.0018 and GDNF vs. GDNF+IS p=0.0315)(Fig. 
4A). We noticed that GDNF alone also caused a significant increase in AT2R mRNA 
(p=0.0121). By contrast, AT1R mRNA levels remained unchanged either by addition of 
trophic factors or IS (Fig. 4B). This result does not preclude post-transcriptional regulation 
that could result in altered protein expression, particularly for AT1R. Furthermore, the 
analysis by PCR does not discriminate between neuronal subpopulations. Thus, it is 
important to analyse AT1 and AT2 receptor expressions in vivo, where the neurons are 
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CFA cutaneous-induced inflammation regulates AT2R expression 
We next examined whether 1- and 4-day CFA-induced cutaneous inflammation altered the 
expression of AT2R in primary sensory neurons. We measured AT2R staining intensity at 3 
locations within each neuron: whole cytoplasm (excluding the nucleus), at the cell edge and 
at the perinuclear region (called inner). Large neurons exhibited very low and invariant levels 
of AT2R (see Suppl. Fig. 3). The whole data set, including the measurements done in single 
neurons, all neuronal sizes and conditions for AT1R and AT2R, plus statistical analyses is 
presented in Supplementary Tables 1 through 4. Note that the bar plots in figures 5 and 6 
show the average %intensity per rat, but the intensity measurements were carried out 
neuron by neuron. 
Representative photomicrographs (Fig. 5A) and detailed quantification (Fig. 5B) revealed 
that overall AT2R cytoplasmic intensity was unchanged in small and medium size neurons. 
However, small neurons showed a significant bilateral increment at the cell edge (55.9±2.4% 
for contralateral and 57.2±1.3% for ipsi) compared to normal (44.6±2.7%, p=0.0052). Mean 
AT2R intensity also increased significantly ipsilaterally relative to normal and contralateral at 
the inner region of small neurons (69.6±1.4 vs. 61.5±1.9 vs. 61.2±2.6, p=0.0057). This 
change in AT2R expression was restricted to small neurons, likely unmyelinated C-neurons.  
At CFA4, unlike CFA1, we found a different AT2R expression pattern. First, there was no 
significant change at any subcellular location in small neurons (Fig. 5C&D). Remarkably, 
medium size neurons showed statistically significant ipsilateral increments in the average 
%intensity of AT2R compared to both normal and contralateral at the whole cytoplasm 
(65.5±1.1 for ipsi vs. 53.6±3.3 for normal vs. 50.2±3.0 for contralateral, p=0.0021) and at the 
cell edge (59.8±1.7 for ipsi vs. 37.3±2.3 for normal vs. 46.1±2.2, for contralateral, p<0.0001). 
At the perinuclear region (inner) we also observed a significant increment in AT2R mean 
intensity relative to contralateral (66.4±1.7, vs. 53.8±3.0, p=0.0081) (Fig. 5D). In summary, 
our results strongly indicate that AT2R expression increased in small neurons at CFA1 and 
in medium DRG neurons at CFA4.  
CFA cutaneous-induced inflammation regulates AT1R expression 
We next studied how cutaneous inflammation affected AT1R expression as its involvement 
in the peripheral response to inflammation remains unclear. 
Fig. 6 summarizes our findings on the expression pattern of AT1R in small, medium and 
large DRG neurons at CFA1 (A) and CFA4 (B). We observed no changes whatsoever in 
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subpopulation, except for a modest increment in whole cytoplasm level contralaterally in 
large neurons (Fig. 6A). Interestingly, at CFA4 we found elevated ipsilateral average 
%intensity of AT1R in large neurons with no changes in small or medium subpopulations. 
This increment was statistically significant for ipsilateral vs. normal and contralateral DRG in 
the cytoplasm (42.7±1.7 vs. 29.6±1.3 for normal and 31.3±2.4 for contralateral, p=0.004). 
Similarly, AT1R levels increased significantly at the cell edge (46.1±2.2 for ipsi vs. 34.5±2.1 
for normal and 34.2±2.0 for contralateral, p=0.0055). Finally, we found elevated inner AT1R 
average intensity for ipsilateral compared to normal (42.5±2.8 vs. 29.3±1.2, p=0.0007). 
Thus, in contrast to the case for AT2R, AT1R expression changed significantly only in large 
neurons and at CFA4. 
In vitro neuritogenesis of DRG neurons depends on AT1R and AT2R 
The extent of skin innervation has been linked to pain sensitivity with inflammation leading to 
an increase in neurite outgrowth. It is also known that inflammation triggers the release of 
Ang-II and that this molecule induces neuritogenesis in several neuronal types, including 
primary sensory neurons (Anand et al. 2013; Chakrabarty et al. 2008; Chakrabarty et al. 
2013). In light of our observations regarding the expression of AT1R and AT2R after CFA-
induced inflammation, we decided to evaluate the roles of these two receptors under 
controlled conditions with cultured DRG neurons. 
To this end, we tested the effect of Ang-II on neurite outgrowth (see Methods). We used 
NGF 7S as a positive control due to its strong neurite outgrowth promoting activity (Delree et 
al. 1989). Figure 7 (A-F) shows representative confocal micrographs of all experimental 
conditions with their staining against -TubIII, AT2R and AT1R plus the mask generated to 
measure total neurite length in each condition. We stained against AT1R and AT2R to 
demonstrate that in vitro DRG neurons maintain the expression of the receptors and also to 
exclude the possibility that a lack of effects of Ang-II was due to receptors down-regulation. 
We did not observe any obvious change in the expression of either AT1R or AT2R. The bar 
plot in Fig. 7G shows the neurite length per neuron under all conditions. As expected NGF 
had a strong neurite-promoting activity (411.1±48.7 µm/neuron) compared to NTF 
(165.5±20.5 µm/neuron, p<0.0001). Ang-II also exhibited statistically significant neuritogenic 
activity compared to NTF (307.3±27.5 µm/neuron, p<0.0043) and was not significantly 
different from NGF. Interestingly, treatment with the AT2R antagonist PD123319 (Ang-
II+PD) and azilsartan (a selective competitive inhibitor of AT1R; Ang-II+Azil) resulted in 
significantly lower average neurite length than with Ang-II alone (154.9±41.8 µm/neuron for 
PD and 174.9±25.2 µm/neuron p<0.003 for Azil). This suggests that Ang-II exerted its 
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completely blocked the activity of Ang-II and the combination was below NTF control, 
although it is not statistically different (p=0.058). Note that we obtained the same pattern of 
neurite outgrowth in the different experimental conditions when measuring neurite length 
using PGP9.5 instead of -TubIII (Suppl. Fig. 4), to control for a possible artefact arising 
from neurite thickness-related staining intensity.  
In vivo pharmacological manipulation of AT1R and AT2R affects peripheral neurite 
density 
To determine whether our findings in vitro were physiologically meaningful, we looked for an 
Ang-II effect on neuritogenesis in vivo. Of note, one study has already established that 
antagonizing AT2R with PD123319 affects CFA-induced neuritogenesis (Chakrabarty et al. 
2013). However, the role of AT1R in this process was not examined. Thus, we evaluated 
whether selective in vivo pharmacological inhibition of AT1R and both AT1R and AT2R 
altered a) the inflammatory response and b) the neurite density of IB4+ and CGRP+ 
terminals.  
Suppl. Fig. 5A shows the induction of edema at CFA1 in the ipsilateral (CI) vs. contralateral 
(CC) hindpaw. Losartan failed to reduce or prevent the formation of this edema (Los I vs. 
Los C) and so did the combination of 4 weeks losartan plus 3 days PD123319 (Los+PD I vs. 
Los+PD C). Another marker of inflammation is the thickness of the epidermal layer, which 
increases after CFA treatment (Leiguarda et al. 2018). At CFA1, we found that the mean 
epidermal thickness increased ipsilaterally under all experimental conditions (Suppl. Fig. 
5B). This confirms our finding that neither chronic low dose losartan nor the combination of 
losartan plus PD at the concentrations we used was effective in reducing or preventing 
edema. We also observed thickened epidermal layer in the contralateral side of losartan-
treated rats compared to control. This may be due to the ability of losartan to induce 
significant elevation in circulating levels of the growth factors receptors EGFR and KGFR 
(Koga et al. 2008). 
Because previous reports showed apparent no change in neurite outgrowth with CFA but 
lacked proper quantification (Chakrabarty et al. 2013) we studied the effect of Los and 
Los+PD on the neurite density of myelinated terminals. We found that the density of 
myelinated terminals increased significantly after CFA in control rats (p=0.0151). This 
increment was not prevented by Los (p=0.0041) but was suppressed by Los+PD (Fig. 8A).  
We also examined the impact of the treatments in IB4+ free terminals (Fig. 8B). As 
expected, control rats exhibited a marked increment in the density of IB4+ neurites 
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in neurite density compared to the contralateral side. These rats also exhibited a much lower 
level of neuritogenesis than control rats (CI vs. Los I, p=0.007). Although there was no 
statistically significant reduction in IB4+ neurite density contralaterally, the trend was for 
these animals to exhibit less neuritogenesis than control rats. Surprisingly, the co-
administration of PD123319 with Los resulted in a drastic reduction of IB4+ neurite density 
contralaterally compared to control (p=0.003). This treatment also resulted in very low levels 
of innervation ipsilaterally, although CFA still caused a significant increment when compared 
to the contralateral foot. Our findings indicate that simultaneously blocking AT1 and AT2 
receptors has a systemic, bilateral arresting effect on neuritogenesis of IB4+ C-neurons. 
Finally, we found that Losartan treatment abolished the ipsilateral up-regulation of 
peptidergic fibers neuritogenesis induced by CFA (there was no difference between Los C 
vs. Los I). The addition of PD did not change this effect (p=0.0519) (Fig. 8C). Therefore, it 




Here we show a full phenotypic characterization of primary sensory neurons that express 
AT2R. We also demonstrate a unique change in the pattern of expression of AT1R and 
AT2R in different neuronal subpopulations at different times in response to cutaneous 
inflammation. We provide the first demonstration of a direct regulation of AT2R in vitro by an 
inflammatory soup and also evidence that GDNF could up-regulate this receptor. We 
establish the co-localization of AT1R and AT2R and examined in detail their interplay as 
mediators of Ang-II induced neurite outgrowth in vitro. We found selective effects of Ang-II 
on in vivo neuritogenesis of non-peptidergic C-fiber neurons, CGRP+ nerve terminals and 
also myelinated fibers by pharmacologically manipulating AT1R and AT2R. Taken together, 
our data indicate that in the DRG neurons exposed to inflammation, AT1R and AT2R act co-
operatively instead of antagonizing each other, as it is the canonical view.  
Our phenotypic multifaceted characterization using antibodies and pharmacological tools 
confirms and expands previous published results showing the presence of AT2R at sites 
where its activation could lead to the regulation of nociception (Anand et al. 2013; Benitez et 
al. 2017; Chakrabarty et al. 2013). Note that the use of commercially available antibodies 
has some limitations (Goodman 2018). The specificity of the antibodies against AT2R and 
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antibodies used in this study (Suppl. Fig. 1). Nonetheless, we acknowledge that the results 
coming from their use must be interpreted with caution. 
Our data show that AT2R is preferentially expressed in non-peptidergic (IB4-binding) likely 
C-nociceptors in line with our previous study (Benitez et al. 2017). The receptor was also 
present in peptidergic (trkA+/SP+) neurons that encompass both small C-nociceptors and 
also medium size A-neurons (Fang et al. 2005a). The latter include the type II A-
mechanoheat units with moderate conduction velocities and higher mechanical and lower 
heat thresholds (Djouhri & Lawson 2004). Low levels of AT2R in a few trkA+/RT97+ large 
neurons may indicate that the receptor was also present in A-nociceptors. These neurons 
are high-threshold mechanoreceptors thought to represent ~20% of all A/ neurons in the 
DRG (Dubin & Patapoutian 2010; Fang et al. 2005b).  
We found that AT1R in all neuronal sizes, although its expression was highest in small 
neurons, in agreement with previous studies (Pavel et al. 2008; Patil et al. 2010). The fact 
that AT1R and AT2R are often present in the same neurons warranted examination of their 
possible interplay in the context of cutaneous inflammation. Our first observation showed 
that exposure of purified DRG cultures to a complex inflammatory soup for 24h caused an 
increment in the mRNA levels of AT2R but not of AT1R. This suggested that a similar 
mechanism might be operating during chronic cutaneous inflammation.  
It is interesting to note that GDNF and its high affinity receptor GDFR1/Ret in IB4+ neurons 
are involved in hyperalgesic priming (Joseph & Levine 2010) and also in persistent muscle 
pain (Alvarez et al. 2012). We found that GDNF stimulates AT2R mRNA synthesis in DRG 
cultures, an observation that agrees with the known GDNF-dependence of survival and 
phenotypic differentiation of IB4-binding neurons (Zwick et al. 2002).  
Our finding that CFA1 increased AT2R expression in small, C-like neurons while CFA4 
increased the receptor expression in medium A-neurons indicates that AT2R is selectively 
and differentially modulated throughout the inflammation process. To our knowledge, this is 
the first time this unique pattern has been reported. Our observed simultaneous increment in 
AT2R at the inner and edge probably indicates enhanced synthesis de novo plus transport 
towards the membrane. This aspect of the change in expression requires further 
examination but agrees with studies showing that enhanced membrane trafficking of pain-
facilitating molecules underlies the response to inflammation and nerve damage (reviewed 
by (Ma & Quirion 2014)). 
In contrast to the pattern seen with AT2R, AT1R expression remained largely unchanged in 
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CFA4. To put this surprising finding in context, other researchers found that in a model of 
CCI the administration of Ang-II led to an increase in the number of large ATF3+ neurons (a 
marker of neuronal damage). This effect was reverted by treatment with losartan but not with 
PD123319 (Pavel et al. 2013). Also, there is evidence that selective activation of non-
nociceptive A neurons can induce neuropathic pain (Tashima et al. 2018). Thus, there is a 
possible functional link between likely A low-threshold mechanoreceptors or may be A-
nociceptors and AT1R, but the underlying mechanism and its physiological meaning remains 
unclear. One possible interpretation for this unique pattern of change in the expressions of 
AT1R and AT2R is that AT2R predominantly expressed in small likely C-fiber neurons is 
initially recruited by the inflammation, producing primary mechanical and heat hyperlagesia 
as part of the nocifensive response to the insult. At 4 days after CFA, the inflammation can 
then recruit large neurons carrying AT1R. This second phase is associated with the adaptive 
response to inflammatory pain, and often involves A-fiber like non-nociceptive neurons. 
Chronic inflammation is associated with pathological pain. One mechanism proposed to 
underlie this connection is that pro-inflammatory mediators promote neuritogenesis of both 
peptidergic and non-peptidergic nociceptors and possibly their sensitization (Anand et al. 
2013). This hyper-innervation has been shown in skin (reviewed in (Hendrix & Peters 2007)) 
and in a model of vestibulodynia (Chakrabarty et al. 2018; Sharma et al. 2018). Thus, we 
decided to examine the impact of Ang-II on DRG neurite outgrowth, first in vitro and then in 
vivo. In our in vitro assays to examine neuritogenesis we found that both AT2R and AT1R 
stimulates neurite outgrowth. This agrees with a previous report that Ang-II enhanced neurite 
outgrowth in cultured DRG neurons, an effect that was prevented by treatment with an AT2R 
antagonist (Anand et al. 2013). A similar role for this receptor was seen in CFA-induced 
vestibulodynia where disruption of the RAS system and antagonism of AT2R attenuated 
neuritogenesis (Chakrabarty et al. 2018; Sharma et al. 2018). Note that CFA-induced 
cutaneous inflammation triggers an elevation in the local levels of renin and 
angiotensinogen, which are released by T-cells and macrophages, recruited to the site of 
inflammation (Chakrabarty et al. 2018; Chakrabarty et al. 2013). Additionally, recent 
evidence shows that macrophages express AT2R which upon activation by Ang-II release 
reactive oxygen/nitrogen species. These alter the function of TRPA1 receptors in sensory 
neurons (Shepherd et al. 2018). Thus, macrophages recruited early during cutaneous 
inflammation may contribute to inflammatory pain via potentiation of the local renin-
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Ang-II was reported to promote neurite growth in hypothalamic neurons through AT1R (Yang 
et al. 2002) although ours is the first report of the involvement of this receptor in DRG 
neuritogenesis. Conversely the AT1R antagonist olmesartan promoted neurite outgrowth in 
cultured fetal ventral spinal cord explants and protected spinal motor neurons in vivo after 
partial axotomy of the sciatic nerve (Iwasaki et al. 2002). Thus, there is an open question as 
to what signal causes AT1R to act neuritogenic. The observation that activation of AT2R 
improves the growth of neurites of cultured corticospinal neurons (Namsolleck et al. 2013), 
may provide a solution to this conundrum if the effect of olmesartan is simply to free AT2R to 
act as neuritogenic. In other words, AT1R may act as a constitutive brake on the 
neuritogenic activity of Ang-II. In support of this interpretation, in NG108-15 cells expressing 
both AT1R and AT2R Ang-II caused neurite retraction, while in those expressing AT2R 
alone it promoted neurite outgrowth (Laflamme et al. 1996). However, this does not appear 
to be the case in DRG neurons, as most of them co-express both receptors and respond to 
activation of either receptor by promoting neurite outgrowth. Nonetheless, experimental 
evidence demonstrates a cross-talk between the two receptors, an aspect linked to the 
differentiation state of cells. 
Our observation that in vivo chronic losartan failed to impair the inflammation-induced 
increment in myelinated terminals while adding the AT2R blockade succeeded, suggests 
that there was a subpopulation of large AT1R+ neurons whose neuritogenesis was 
independent of Ang-II. However, the fact that blocking both receptors prevented CFA-
induced neurite growth of these neurons suggests the existence of a paracrine control 
mechanism involving AT2R. We speculate that an unknown factor released by AT2R+ 
neurons (different from Ang-II) may be controlling the neuritogenesis in these large 
myelinated neurons. An alternative interpretation is that the subpopulations that respond to 
inflammation are the A and A-nociceptors which would be affected by dual receptor 
blockade but not by AT1R blockade alone, as the neurite outgrowth in large neurons 
appears to be Ang-II independent. 
Here we provide the first demonstration that IB4+ C-fiber cutaneous innervation depends (at 
least partially) on recruiting AT1R and AT2R upon CFA-induced release of Ang-II. As IB4+ 
neurons mediate mechanical and heat hyperalgesia in the rat (Cavanaugh et al. 2009; 
Tarpley et al. 2004) any significant alteration in their nerve endings (length, reach and 
branching) might affect their ability to respond to noxious stimuli. This agrees well with 
previous reports indicating that antagonizing AT2R with EMA401 reduced mechanical 
allodynia in a rat model of CFA (Anand et al. 2015) and also proved efficacious in the 
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previous studies have associated AT1R with neurite outgrowth of IB4+ neurons. One report 
showed that blockade of the AT1 receptor with losartan in a rat model of CCI prevented 
tactile hyperalgesia and attenuated cold hyperalgesia, but failed to affect the response to 
noxious heat stimulus (Pavel et al. 2013). Thus, we propose that a reduction in the neurite 
length of IB4+ neurons may underlie this effect. One unexpected result was the significant 
reduction in contralateral IB4+ neurites with the dual blockade. This might result from a more 
substantial systemic effect on the contralateral side, while other neurite-promoting molecules 
(RAS-independent) are active ipsilaterally.  
Regarding peptidergic nerve endings (these include C, A and some A trkA+ nociceptors) 
we found that AT1R blockade abolished the ipsilateral up-regulation of neuritogenesis 
induced by CFA. Surprisingly, addition of AT2R blockade did not modify this effect. Note that 
treatment with PD123319 alone in CFA-treated rats showed that AT2R is involved in CGRP-
like long-term hyperinnervation of the skin (Chakrabarty et al. 2013). However, unlike our 
study, these authors did not examine either the effect of blocking AT1R alone or both 
receptors. Thus, it is possible that the discrepancy between our findings and theirs is due to 
the interplay between the receptors.  
Additionally, as we performed the in vitro studies in P15 DRG neurons and the in vivo 
pharmacology in P90 rats, discrepancy in the results might be expected reflecting age-
related differences in physiology. However, what we observed in vivo confirms what we 
found in vitro. 
Accumulating evidence suggests that regulation of mutually antagonistic AT1R and AT2R is 
essential for maintaining control of inflammation and that an imbalance between these two 
receptors is potentially pathological (Smith & Missailidis 2004). Most papers in the literature 
have focused on either AT1R or AT2R but it is important to remember that any C- or A-fiber 
neuron exposed to Ang-II will have both receptors activated simultaneously. Depending on 
the relative levels of the two receptors (variable amongst neuronal subpopulations and 
pathologies) and how they affect each other the net outcome of their activation can be very 
different. Thus, the key may lie in the balance between the level of expression and activity of 
the two receptors. Using an experimental paradigm similar to ours, (Hashikawa-Hobara et al. 
2012) showed that administration of the AT1R blocker candesartan improved Ang-II pro-
neuritogenic activity mediated via AT2R. 
In conclusion, ARBs have recently been promoted as potential drugs to alleviate chronic 
pathological pain associated with nerve injury and inflammation. However, most studies 
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particularly relevant for patients using anti-hypertensive regimes based on ARBs (mostly 
AT1R antagonists) who rely on AT2R antagonists as a palliative for pain. Given the range of 
neuronal subpopulations expressing AT1R and AT2R, their co-localization in these neurons 
and their significant interplay, it might be beneficial to examine mechanoperception and 
proprioception and the presence of paresthesia/dysesthesia in these patients. 
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Figure legends 
Figure 1: Time-line diagram of the in vivo pharmacological experiments 
18 adult female rats were randomly allocated (using simple sequence randomization) to 3 
experimental groups of 6 rats each. The control group received normal drinking water (NDW) 
during 28 days; the second group was given an effective oral dosage of 20 mg/kg Losartan 
to inhibit AT1R. The third group was treated as the second with the administration of a daily 
dose of 1 mg/kg PD123319 (PD) from days 25 to 28. This allowed us to examine the effect 
of antagonizing AT1R and AT2R at the same time. On day 28, all rats received a single 
intradermal injection of CFA in the hindpaw and were all culled 24h later for tissue 
harvesting. 
Figure 2: Phenotypic characterization of normal L5 DRG neurons expressing AT2R 
and their correlation with AT1R.  
(A-B) Representative photomicrographs of ABC/DAB staining of AT2R and AT1R. Black 
arrows: AT2R+ neurons. Asterisks: AT2R- large neurons. Plots of either AT2R (n=117 
neurons) or AT1R (n=223 neurons) cytoplasmic %intensities versus cross-sectional areas 
(in m2). Spearman´s correlation values (rs) and level of significance are indicated in each 
plot. Horizontal dotted lines mark the limit between negatively stained (intensity <20%) and 
positively stained neurons (≥20%). (C) Co-localization of AT2R and AT1R. AT2R+/AT1R+ 
neurons are indicated by white arrows. The bar graph shows the proportions of AT2R+ 
neurons that are also AT1R+ and vice versa. (D) Triple immunofluorescence for AT2R, IB4-
binding and trkA. There are AT2R+ neurons positively stained against trkA, IB4 or both 
phenotypic markers. (E) Plots show that cytoplasmic %intensities of AT2R significantly and 
positively correlate with IB4 but not with trkA (n=118 neurons). In the trkA plot, dotted lines 
indicate 3 neuronal groups: negatively stained neurons (<20%), weakly trkA+ neurons (20-
40% intensity) and strongly trkA+ (>40%). (F) Triple immunofluorescence confocal 
photomicrographs stained against AT2R, RT97 and trkA. The white arrow points to a 
possible A-nociceptor. Significance is ***p<0.001. 
Figure 3: Central and peripheral projections of AT2R+ peptidergic and non-
peptidergic DRG neurons. 
Double immunofluorescence for AT2R (red) and IB4-binding (green) in normal spinal cord 
(A), dorsal root (B), spinal nerve (C), sciatic nerve (D) and skin (E). There was a modest 
overlap in the lamina Iii inner (LIIi) between AT2R and IB4. White arrows indicate co-
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Asterisk in E corresponds to a nerve bundle. (F-H) Double immunofluorescence against 
AT2R (red) and Substance P (SP, green) in: spinal cord (F), dorsal root (G) and spinal nerve 
(H). There was a significant overlap in the lamina I (LI) and II outer (LIIo) between AT2R and 
SP. Most AT2R+ fibers were also stained for SP, as indicated by white arrows. Arrowheads 
indicate AT2R+ and SP- fibers. 
 
Figure 4: Inflammatory soup increased AT2R but not AT1R expression in DRG 
neurons in vitro. 
(A) Top: representative PCR blot showing the expression of AT2R mRNA in purified DRG 
cultures under three experimental conditions (No trophic factor or NTF, 10 ng/ml NGF and 
20 ng/ml GDNF) with and without the addition for 24h of an Inflammatory Soup (IS). Adrenal 
gland tissue (Adr) was used as a positive control. Bottom: bar plot showing the ratio of AT2R 
to -actin relative mRNA levels. Addition of the IS resulted in increased levels of AT2R 
mRNA in all experimental conditions. GDNF alone was also able to significantly increase 
AT2R mRNA. (B) Top: as in (A), but for AT1R. Bottom: neither the addition of trophic factors 
nor the IS changed the amount of AT1R mRNA relative to -actin. Bars to the left side of the 
blots indicate the ladder weight expressed in bp. Data from 3 separate cultures from 3 rats 
(n=3). Significance is as follows *p<0.05, #, **p<0.01. 
Figure 5: One- and four-days Complete Freund´s Adjuvant (CFA) affected AT2R 
expression in different subpopulations of DRG neurons  
(A) and (C) Representative photomicrographs of ABC/DAB staining of AT2R in normal (not 
treated, N), contralateral (C) and ipsilateral (I) L5 DRG mid-sections after one (A) and four 
(C) days of CFA-induced cutaneous inflammation (CFA1 and CFA4). Black arrows: neurons 
with very weak or absent staining at the cell edge and a high concentration in the perinuclear 
region. (B) and (D) Bar plots of AT2R intensities at three sub-cellular regions (whole 
cytoplasm, cell edge and inner) in DRG neurons of N and CFA1-4 (C and I) rats. Each dot 
represents the average %intensity of numerous neurons belonging to a single rat. The plots 
show data from 5 untreated rats, 5 CFA1 and 5 CFA4 rats (a dot per rat) and the 
mean±SEM. At CFA1 only small neurons showed a significant increment in AT2R intensity 
at the edge and inner regions with no changes in medium neurons. At CFA4 medium size 
neurons showed a significant increment in AT2R intensity at the edge and inner regions 
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Figure 6: Cutaneous inflammation increased AT1R expression only at CFA4 and in 
large L5 DRG neurons 
Bar plots of AT1R %intensities at whole cytoplasm, cell edge and inner at CFA1 (A) and 
CFA4 (B). Comparisons were made with normal DRGs (from untreated rats, N) and also 
between the contralateral (C) and ipsilateral (I) side of the animal. The plots show the 
mean±SEM from 5 untreated rats, 5 rats at CFA1 and 5 rats at CFA4. Each dot represents 
the average %intensity for a single animal. Notice that, unlike AT2R, CFA1 had no overall 
effect on AT1R expression. However, at CFA4 only large neurons underwent a significant 
elevation of AT1R expression, with no changes seen in small or medium size neurons. 
Significance is as follows *p<0.05 and **p<0.01. 
Figure 7: AT1R and AT2R contributed to the increase in neurite length induced by 
Ang-II in DRG neurons in vitro. 
Representative confocal micrographs of all 6 experimental conditions are shown: no trophic 
factors (A), NGF (B), Ang-II (C), Ang-II+PD123319 (D), Ang-II+Azilsartan (E) and Ang-
II+PD123319+Azilsartan (F). The far right column shows the masks generated to measure 
the total neurite length in each experimental condition. (G) Bar plot shows the neurite length 
(μm) per neuron in all conditions. Ang-II promoted neurite outgrowth in these neurons, an 
effect that was reverted by blocking AT1R with azilsartan and also by inhibiting AT2R with 
PD123319. Each dot represents the average neurite length measured in the neurons of 1 
coverslip. Data from 3 separate cultures from 3 independent rats. Significance is as follows 
*p<0.05, **p<0.01 and ***p<0.001. 
Figure 8: In vivo AT1R and AT2R antagonists altered the CFA-induced increment in 
neurite density of the hindpaw skin. 
Representative photomicrographs of ipsilateral skin of the hindpaw with (A) RT97 and DAPI; 
(B) IB4-binding and -TubIII; (C) CGRP and -TubIII. Three experimental groups are shown: 
CFA1, CFA1 in rats pre-treated with oral losartan (CFA+Los) and CFA1 in rats pre-treated 
with oral losartan plus i.p. PD123319 for 3 days prior to CFA injection (CFA+Los+PD). Bar 
plots show the density of the visible nerve terminals for each marker in the contralateral and 
ipsilateral paw in the three experimental groups (n=6 rats per group). White arrows point to 
nerve terminals that were quantified. Dotted lines demarcate the limit between the epidermis 
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